Patient-derived xenograft (PDX) models have been established from the world’s largest living tumor bank at Molecular Response and used to mimic clinical trial settings with patients from diverse populations and heterogeneous disease; these models are being used to test novel compounds in a more predictive preclinical setting. Overall, the collection is comprised of 144,000 tumor samples corresponding to 70,000 unique patients, and includes >350 PDX models. Crown Bioscience acquired these PDX models and has exclusive CRO access to the Mol Response living tumor bank at Molecular Response and used to mimic clinical trial settings with different patients. The PDX models are being used to test novel compounds in a more predictive preclinical setting.

Conclusions

- World’s largest & most diverse PDX collection
- >1,600 PDX Models
- Mirror global clinical population
  - Geographic: Asia, Europe, US
  - Clinical: Late stage, metastatic, prior treated
- Biomarker: Mutational diversity captured and NGS characterized
- Rapid & On-demand PDX Growth
- Access to 144,000 ‘Living Tumor Bank’ enables rapid studies of cancer populations
- Development path of 1,000s PDX models per year
- Client driven/sponsored PDX creation

- Population studies enable confident preclinical rational for clinical development strategy
  - Patient selection criteria
  - Biomarker/companionDx
  - Combination therapies
  - Candidate prioritization
  - Resistance delay